Garware Fulflex has completed the acquisition of a 300,000‑square‑foot fully automated medical products facility in Jacksonville, Texas, doubling its projected global revenue and expanding its footprint in the world’s largest healthcare market.

Key Takeaways

  • Garware Fulflex finalised purchase of a 300,000‑sq‑ft automated medical manufacturing plant
  • Deal expected to lift global revenue from ~US$100 M to ~US$200 M
  • More than 250 local employees now part of the Fulflex family

Pune, India – On July 10, 2026, Garware Fulflex announced the successful closure of its acquisition of a 300,000‑square‑foot, fully‑automated medical‑products facility located in Jacksonville, Texas. Situated on a 30‑acre campus, the plant adds a significant North‑American manufacturing node to the company’s rapidly expanding global healthcare portfolio.

Strategic Context

Garware Fulflex, an Indian‑headquartered leader in engineered polymer solutions for medical devices, PPE, and rehabilitation equipment, already operates 14 sites worldwide, including four U.S. factories, two in India, and one in the Dominican Republic. The Jacksonville site brings advanced injection‑molding, blow‑molding, thermo‑forming, extrusion, assembly, and quality‑control systems under one roof, enabling the firm to meet stringent FDA and international standards while scaling production of critical medical components.

Economic Impact and Workforce Integration

Industry analysts estimate that the acquisition will double Garware Fulflex’s annual turnover—from roughly US$100 million to US$200 million—by unlocking new capacity and enhancing supply‑chain resilience for its global clientele. The plant currently employs more than 250 skilled workers, all of whom have been welcomed into the Fulflex family, reinforcing the company’s commitment to local job creation and talent development.

Future Outlook

With the world’s healthcare spending accelerating and regulatory environments tightening, manufacturers are compelled to invest in automation, digital twins, and AI‑driven quality assurance. Chairperson Diya Garware Ibanez described the transaction as “a defining milestone in our journey to build a globally respected healthcare manufacturing company.” She added that the new facility will serve as a hub for innovation, operational excellence, and long‑term growth, positioning Garware Fulflex as a strategic partner for leading multinational medical‑device firms.

Conclusion

The Jacksonville acquisition not only expands Garware Fulflex’s production capacity but also deepens its proximity to the United States—the largest healthcare market on the planet. As demand for high‑quality, cost‑effective medical products surges, such large‑scale deals are likely to shape the competitive dynamics of the global health‑tech ecosystem.